Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $80000.0.

  • Cue Biopharma's Depreciation & Amortization (CF) fell 2079.21% to $80000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $378000.0, marking a year-over-year decrease of 825.24%. This contributed to the annual value of $397000.0 for FY2024, which is 2859.71% down from last year.
  • As of Q3 2025, Cue Biopharma's Depreciation & Amortization (CF) stood at $80000.0, which was down 2079.21% from $99000.0 recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Depreciation & Amortization (CF) ranged from a high of $318000.0 in Q1 2021 and a low of $80000.0 during Q3 2025
  • In the last 5 years, Cue Biopharma's Depreciation & Amortization (CF) had a median value of $136000.0 in 2023 and averaged $179613.8.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 2217.49% in 2021, then tumbled by 4433.5% in 2023.
  • Over the past 5 years, Cue Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $309662.0 in 2021, then crashed by 34.44% to $203000.0 in 2022, then crashed by 44.33% to $113000.0 in 2023, then fell by 13.27% to $98000.0 in 2024, then dropped by 18.37% to $80000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $80000.0 in Q3 2025, compared to $99000.0 in Q2 2025 and $101000.0 in Q1 2025.